Fast Market Research recommends "Pipeline: Renal Cell Cancer" from Datamonitor, now available

Boston, MA -- (SBWire) -- 03/15/2013 --Seven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to produce durable responses in RCC patients and only delay progression. As a consequence, effective treatment options capable of sustaining responses in RCC are still required.

Report Scope

- Analysis of late-stage pipeline drugs including a comparison of clinical and commercial attributes to determine competitiveness in the marketplace.
- Identifying key trends, clinical trial design and innovative early-stage projects.
- Predictions on how future treatment may emerge.
- Review of candidates in development for renal cell cancer across the US, Japan, and five major EU markets.
- Insight from several key opinion leaders

View Full Report Details and Table of Contents

Report Hightlights

Datamonitor has identified 63 drugs currently in development for RCC, of which 38 are targeted therapies, 15 are immunotherapies, five are cytotoxic therapies, four are cancer vaccines, and one is a gene therapy.

AGS-003, IMA901 and BMS-936558 currently in Phase III development for RCC are just some of the drugs discussed within this Datamonitor Healthcare report.

Reasons to Get this Report

- What key trends are emerging for the future treatment of renal cell cancer?
- What are the most popular targets for early-stage pipeline drugs?
- What are the strengths, weaknesses, opportunities and threats of phase 3 drugs?
- How do phase 3 drugs compare to the current standard of care?

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2012
- Metastatic Renal Cell Cancer - Pipeline Review, H2 2012
- Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012
- Renal Cell Carcinoma - Pipeline Review, H1 2012
- R&D Trends: Renal Cell Cancer - Crowded RCC market remains attractive to drug developers
- Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2012
- Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2012
- Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012
- Small-Cell Lung Cancer - Pipeline Review, H1 2012
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion